59 results about "Thyroid function" patented technology

The invention discloses a group of blocking monoclonal antibodies of an SH1 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR) as well as a preparation method and application of the blocking monoclonal antibodies of the SH1 homologous cluster fully human thyrotropin receptor (TSHR). The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH receptor blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; expression and fibrosis of effector cell orbital fibroblasts TSHR for inhibiting thyroid-related eye diseases are remarkably relieved, and wide application prospects are achieved in treatment of Graves' diseases and diseases such as thyroid eye diseases caused by hyperthyroidism.

The invention discloses a group of blocking monoclonal antibodies of a CHK36 homologous cluster fully human TSH receptor (TSHR) as well as a preparation method and application of the blocking monoclonal antibodies. The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH-blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells, so as to obtain the TSHR-TBAb-TSHR-TBAb. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the synthesis and secretion of thyroid hormone are inhibited; according to the present invention, with the application of the compound, the expression and the fibrosis of the effector cell orbit fibroblast TSHR inhibiting the thyroid-related eye disease can be significantly reduced, and the wide application prospect is provided in the treatment of Graves' disease (Graves' disease, GD) and diseases caused by hyperthyroidism, such as thyroid eye disease (thyroid eye disease, TED), and the like.

The invention discloses a traditional Chinese medicine composition for treating hyperthyroidism and a preparation method thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for treating hyperthyroidism is prepared from cyclodextrin grafted modified hollow mesoporous organic silicon nanoparticles, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution, the cyclodextrin-grafted modified hollow mesoporous organic silicon nano-particles are used as a carrier, traditional Chinese medicine ferment powder and a traditional Chinese medicine extracting solution are loaded, the medicine concentration of a focus part is increased, traditional Chinese medicine ingredients are rapidly released through rapid response fracture of tetrasulfide bond functional groups, and the traditional Chinese medicine composition is prepared in an active targeting and fixed-point blasting mode. The bioavailability and the onset time of the medicine are improved, the leakage risk of the medicine is jointly reduced through the gating effect of cyclodextrin and responsive release of tetrasulfide bonds, synthesis of thyroid hormone is more thoroughly inhibited under the precise effect of high-concentration medicine and multi-target immunoregulation of traditional Chinese medicine, and the recurrence rate of hyperthyroidism is reduced.

The invention provides application of thyroid hormone in preparation of a medicine for treating GJB2 gene mutation related congenital deafness. Experiments prove that injection of the thyroid hormone T3 or T4 can effectively treat congenital deafness and cochlea structure development disorder caused by GJB2 gene mutation, new indications of the thyroid hormone except for hypothyroidism and thyromegaly are expanded, and the application of the thyroid hormone T3 or T4 in treating the congenital deafness caused by GJB2 gene mutation has the advantages that the application of the thyroid hormone T3 or T4 in treating the congenital deafness caused by GJB2 gene mutation has good application prospects. Compared with a traditional treatment scheme, the cochlea dysplasia of the patient can be treated while the hearing of the patient is improved, and a new treatment way is provided for related congenital deafness caused by GJB2 gene mutation.

The present invention discloses a composition for treating hypothyroidism. The formula includes: placenta, antler, Pseudostellaria baicalensis, Salvia miltiorrhiza, and Herba Lycopodii. The prescription of the present invention is demonstrated to have therapeutic effects on hypothyroidism from both traditional Chinese medicine and modern medicine perspectives: from the perspective of traditional Chinese medicine, the efficacy of the present invention in replenishing qi and blood, regulating yin and yang, tonifying kidney essence, filling the marrow sea, and unblocking meridians is unique in treating goiter. From the perspective of modern medicine: Panlushending Jiawei Decoction has the effects of promoting cell reproduction, differentiation, and repairing damaged cells, and is also anti-apoptotic. It also has the effects of promoting the regeneration of vascular endothelial cells, forming new blood vessels, increasing blood flow rate, increasing blood supply, and increasing the secretion and synthesis of thyroid hormones. It can also increase the level of free hormone reabsorption from the intestine and lower the concentration of antibodies.

The invention discloses a method and system for processing thyroid function data based on a spectrum technology, and relates to the technical field of artificial intelligence, and the method comprises the steps: collecting a face video through employing a near infrared spectrum imaging technology, determining a face core region in the face video, and obtaining a face core region; the method comprises the following steps: capturing an absorption energy spectrum characteristic value of a human body trace substance in a human face core area to specific wave band light, obtaining spectrum original data associated with thyroid function, and synchronously recording age information of an acquisition object; on the basis of the preset rule, in combination with the age information of the collection object and the substance detection index related to the thyroid function, the thyroid function state of the collection object is graded and judged to obtain the graded judgment result, and the problem that thyroid function data cannot be processed based on the spectrum technology in the prior art is solved.

The application relates to the technical field of ultrasonic image analysis, and discloses a thyroid nodule evaluation system based on ultrasonic images. The system obtains medical record data and medical examination data of a patient through a multidimensional acquisition module, classifies and forms a data set, analyzes the thyroid function state of each patient through an intelligent evaluation module, generates a function coefficient, analyzes the picture quality of each group of ultrasonic images again, generates corresponding detection data group Jcsj, establishes a unified evaluation standard, quickly screens out key frames from a large amount of ultrasonic image data, has high multidimensional integration efficiency, sets a fixed range threshold value for the intelligent evaluation module, analyzes and generates a nodule volume and a nodule score in combination with a medical data set, and in combination with the function coefficient, the detection data group and the nodule score, evaluates the risk grade of the thyroid nodule and the picture quality of the ultrasonic image of the patient, screens out key frames of the ultrasonic image, and outputs a treatment suggestion; and the intelligent evaluation has high precision.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

The present disclosure relates to the field of clinical detection technology, in particular, to the application of triiodothyronine autoantibody as a marker of thyroid dysfunction during cancer treatment. The present disclosure can help clinicians to judge the real thyroid function status of patients and improve the accuracy of diagnosis.

The invention discloses a novel serum metabolite composition based on dried blood spot detection and elaborates application of the serum metabolite composition as a marker in preparation of a congenital hypothyroidism diagnostic reagent or kit. The serum metabolite composition comprises thyroxine, 2-piperidone and phosphorylcholine PC (14: 0 / 20: 4). The serum metabolite composition can be used for screening and diagnosing patients with the congenital hypothyroidism, and has the characteristics of low detection cost, good repeatability and relatively high sensitivity and specificity.

The utility model discloses a thyroid function measuring and counting device which comprises a measuring instrument and a counter which are movably connected with each other, a lifting handle is fixedly connected to the center of the top of the measuring instrument, a display screen is arranged on the left portion of the front face of the measuring instrument, and a connecting block is arranged on the right portion of the surface of the measuring instrument. A butt joint block is fixedly connected to the upper portion of the back face of the connecting block, and a butt joint inserting groove is formed in the surface of the connecting block. According to the utility model, the butt joint block is arranged on the back surface of the counter, the butt joint block is inserted into the butt joint slot on the surface of the connecting block, and then the positioning insertion rod is inserted into the positioning hole, so that the counter is further fixed, the stability of the counter after being installed is ensured, and during the installation operation, the limiting stop block is blocked outside the storage groove, so that the counter is prevented from being damaged. And the first telescopic rod cannot move backwards, so that when people insert the counter, the connecting block cannot move backwards, and the installation work of people is further facilitated.

The present application relates to the technical field of traditional Chinese medicine, and in particular, to a traditional Chinese medicine composition, a method for preparing same, and use thereof in preparing a medicament for preventing and treating a thyroid disease. The traditional Chinese medicine composition consists of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix. The method comprises: mixing and crushing formulation amounts of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix; or extracting formulation amounts of Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix. The compounding of the four traditional Chinese medicines, Ranunculi Ternati radix, Taraxaci herba, Cyperi rhizoma, and Semiaquilegiae radix, can significantly treat hypothyroidism, thyroid nodules, and the like caused by insufficient thyroid hormones. Compared with the prior art, the traditional Chinese medicine composition features clear ingredients, good safety, and better therapeutic effects, providing technical support for the treatment of thyroid diseases with traditional Chinese medicines.

To provide a method for diagnosing a thyroid dysfunction based on an electrocardiography.SOLUTION: The method for diagnosing a thyroid dysfunction based on an electrocardiography includes: a step S100 for acquiring an electrocardiographic data; and a step S110 for estimating a disease rate of a thyroid dysfunction on a measurement target of the electrocardiographic data based on the electrocardiographic data using a pre-learnt neural network model. The neural network model is learnt based on a correlation between the thyroid function and a change in the electrocardiographic performance.SELECTED DRAWING: Figure 3

The present invention is based on the realization and verification that inhibition of Luteinizing hormone (LH) and / or luteinizing hormone / choriogonadotropin receptor (LHCGR) is useful in the treatment, alleviation or prevention of different medical states related to perimenopause and menopause in women or hypogonadism in men. Thus, an aspect of the present invention relates to LH and / or LHCGR inhibitors for use in the treatment of postmenopausal osteoporosis in a female subject. Another aspect relates to LH and / or LHCGR inhibitors for use in the reduction of fat mass in a postmenopausal female subject. A further aspect relates to LH and / or LHCGR inhibitors for use in the treatment, hypergonadotropic hypogonadism in a male subject. In addition, another aspect relates to LH and / or LHCGR inhibitors for use in the treatment of symptoms of perimenopause and / or postmenopause such as hot flashes, night sweats, osteoporosis, weight gain, hypothyroidism, conversion of T4 to T3, and / or primary hyperparathyroidism.

The invention discloses a group of blocking monoclonal antibodies of an SH23 homologous cluster fully human thyrotropin receptor (TSHR) (a TSH receptor, TSHR), a preparation method of the blocking monoclonal antibodies, and an application of the blocking monoclonal antibodies of the SH23 homologous cluster fully human thyrotropin receptor (TSHR), the SH23 homologous cluster fully human thyrotropin receptor (TSHR) and the preparation method of the blocking monoclonal antibodies. The method comprises the following steps: sorting plasma cells and memory single B cells for specifically recognizing TSHR in peripheral blood of a patient with high TSH-blocking antibody (TBAb) titer by using flow cytometry, cloning antibody light and heavy chains in vitro and performing recombinant expression, and performing antibody property screening verification by using hTSHR-CHO cells, so as to obtain the TSHR-TBAb-TSHR-TBAb. The blocking monoclonal antibody specifically targeting the human TSHR is obtained. The fully human TSH receptor blocking monoclonal antibody disclosed by the invention can be specifically combined with TSHR, and can effectively block signal transduction after the TSH is combined with the receptor; the compound disclosed by the invention has good inhibitory activity in vitro and in vivo experiments, and has a wide application prospect in the aspect of treating Graves' diseases (Graves' disease, GD) and diseases caused by hyperthyroidism, such as thyroid eye diseases (thyroid eye disease, TED) and the like.

Hyperthyroid diarrhea refers to hyperthyroid diarrhea, which is mostly intractable diarrhea, due to excessive thyroid hormone causing increased intestinal peristalsis excitability and diarrhea when the thyroid function is increased, which is caused by endocrine metabolic disorder leading to gastrointestinal function disorder. The present application studies and observes the treatment effect of kaempferol coupling derivative JC-1 on diarrhea of hyperthyroid model mice, and provides a new drug treatment option for diarrhea type colon dysfunction.

The present invention relates to the field of antibody technology, and specifically to a method for preparing and applying a recombinant monoclonal antibody against rT3. The present invention utilizes phage display technology to screen and obtain the rT3 recombinant rabbit monoclonal antibody of the present invention, wherein the heavy chain variable region thereof has the amino acid sequence shown in SEQ ID NO:1; and the light chain variable region thereof has the amino acid sequence shown in SEQ ID NO:2. The monoclonal antibody has strong specificity and high detection sensitivity, and solves the problem of low rT3 content in samples and high detection difficulty. It has been identified that repeated multiple detections using the monoclonal antibody have good stability and high accuracy. The antibody is used for the detection of rT3 content in serum, and combined with other thyroid index tests and clinical manifestations, it can diagnose hyperthyroidism and hypothyroidism, and is also clinically significant in the detection of diabetes, lung infection, myocardial infarction, cirrhosis, uremia, and some cancers.

The invention discloses an oral traditional Chinese medicine prescription for treating thyroid nodules, and relates to the field of traditional Chinese medicine medical science, the oral traditional Chinese medicine prescription is used for treating thyroid nodules and related complications, and the oral traditional Chinese medicine prescription comprises 90-100 g of a liver-soothing and depression-relieving matrix used for relieving liver depression, qi stagnation and depression emotion; the tranquilizing and allaying excitement matrix is used for treating anxiety, insomnia and dreaminess; 165-175 g of a phlegm-reducing and stasis-resolving matrix, which is used for removing turbid phlegm and dissipating caking; the anti-inflammatory guiding medicine substrate is used for diminishing inflammation and guiding medicines of the liver-soothing and depression-relieving substrate, the tranquilizing and allaying excitement substrate and the phlegm-reducing and stagnation-resolving substrate to move upwards to the thyroid gland; wherein the anti-inflammatory guide medicine matrix comprises 15g of radix isatidis, 6g of radix scutellariae, 15g of radix puerariae, 12g of radix platycodonis and 15g of fructus arctii. The prescription has the effects of regulating qi and blood, gradually improving thyroid functions, reducing thyroid nodules and improving the living quality of patients through a synergistic effect, and manifests the essence of comprehensive conditioning of traditional Chinese medicines.

The invention relates to an application of a traditional Chinese medicine composition in preparing a medicine for treating thyroiditis, which is characterized in that the traditional Chinese medicine composition is prepared from astragalus membranaceus, dried ginger, salted morinda officinalis, cortex dictamni, calcined oyster shell, schisandra chinensis and divaricate saposhnikovia root. The composition can obviously improve the thyroid functions of mice and rats, obviously reduce the content of inflammatory factors TNF-alpha, IL-6 and IL-12 in serum of the mice, obviously increase the level of TGF-beta in serum of the rats and reduce the level of IL-17, and has a good treatment effect on autoimmune thyroiditis induced by combination of thyroglobulin and high-iodine water.

The invention relates to the technical field of biomedicine, and provides an adenovirus vector-based TPOAb positive animal model construction method which comprises the following steps: (1) constructing a TPO overexpression adenovirus vector; (2) injecting the TPO overexpression adenovirus vector into the body of an experimental animal, and inducing the generation of TPOAb; and (3) determining the optimal injection dose through a gradient dose experiment, and constructing a TPOAb positive animal model. The TPOAb positive animal model has the advantages that the generation of TPOAb in an animal body is induced by utilizing the TPO overexpression adenovirus vector through a nucleic acid immune technology, and the TPOAb positive animal model which is high in stability and modeling rate and does not interfere with the thyroid function is constructed.

Provided are a group of fully human thyrotropin receptor (TSHR) (TSH receptor, TSHR) blocking monoclonal antibodies belonging to a SH1 homocluster, a preparation method therefor, and a use thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and individual memory B cells, which specifically recognize TSHR, from peripheral blood of a patient having a high TSH receptor blocking antibody (TBAb) titer, cloning antibody light and heavy chains in vitro, followed by recombinant expression, and performing antibody characteristic screening and verification by using hTSHR-CHO cells, thereby obtaining blocking monoclonal antibodies that specifically target human TSHR. The fully human TSH receptor blocking monoclonal antibodies can specifically bind to TSHR, thereby enabling effective blockage of signal transduction after TSH binds to the receptor, inhibiting the synthesis and secretion of thyroid hormones, and significantly reducing and suppressing the expression of TSHR and fibrosis in orbital fibroblasts, the effector cells in thyroid-related eye diseases. The present invention has broad application prospects in the treatment of Graves' diseases and diseases caused by hyperthyroidism, such as thyroid eye diseases.

This disclosure broadly relates to the field of clinical testing technology, and more specifically, to the application of thyroxine autoantibodies as biomarkers of thyroid dysfunction during cancer treatment. This disclosure can help clinicians determine a patient's true thyroid function status and improve diagnostic accuracy.

This invention provides an intelligent auxiliary diagnostic system for thyroid function based on small-sample ultrasound images, belonging to the field of auxiliary diagnostic technology. The system first acquires a thyroid dataset consisting of n cases to construct a small-sample thyroid ultrasound image dataset; then, it constructs a thyroid function classification model based on the EfficientNet-B0 model; this classification model adds a CBAM attention module, a layer normalization layer, an embedding layer, and a Dropout layer to the original EfficientNet-B0 model; the classifier uses independent linear layers; the thyroid function classification model is then trained based on the thyroid ultrasound image dataset; finally, unlabeled thyroid ultrasound images are acquired, and the trained thyroid function classification model is used to classify thyroid function. This system can achieve comprehensive screening of thyroid function.

Wearable Device for Indirect Thyroid Function Assessment

According to an embodiment of the present application, as a method of determining whether to output an alert of a user's thyroid dysfunction, there may be provided a thyroid dysfunction monitoring method including receiving a user's medication information from an external device; selecting a monitoring algorithm to be used to determine whether to output the alert on the basis of the medication information; and determining whether to output the alert on the basis of the selected monitoring algorithm.

Described herein are compositions, pharmaceutical compositions, kits, and methods of use relating to anti-Dio3os antisense RNA. In embodiments, antisense Dio3os compositions, kits, and methods are described to improve symptoms of osteoporosis, for example, osteoporosis induced by a disorder characterized by a thyroid hormone imbalance (i.e., hyperthyroidism or hypothyroidism). In embodiments, antisense Dio3os compositions, kits, and methods are described to improve sensitivity of cancer cells to anti-cancer therapeutics, for example, sensitivity of ER+ breast cancer or other breast cancer cells, thyroid cancer cells, prostate cancer cells, hepatocellular cancer cells, pancreatic cancer cells, and ovarian cancer cells that are sensitized or otherwise non-responsive to cancer therapeutics (for example, aromatase inhibitors or HDAC inhibitors). Combination therapies are also contemplated utilizing antisense RNA according to the present disclosure and other drugs, for example, thyroid and anti-cancer medications.

The invention provides a method for constructing an adult thyroid organ by using a novel thyroid organ culture medium. Specifically, the invention provides a thyroid organ culture medium, a kit and a culture method thereof, by adding special additives FGF2, Y27632 and BMP-4, cells with dryness are induced from tissues derived from adult thyroid, and thyroid organs closer to thyroid tissues are successfully obtained. Compared with the prior art, the thyroid organoid provided by the invention has the advantages that the number is obviously increased, the volume is larger, follicular structures closer to thyroid tissues in morphology can be observed, more thyroid functional proteins can be expressed, the passage frequency is more, the passage time is longer, and the application range is wider. The method has wide application prospects in the fields of establishment and passage of adult thyroid organs, research of thyroid or thyroid-related diseases and drug sensitivity screening of thyroid-related diseases.

The invention relates to the technical field of Chinese patent medicines for treating subacute thyroiditis, and discloses a heat-clearing and goiter-eliminating ointment for treating subacute thyroiditis and a preparation method and application thereof.The heat-clearing and goiter-eliminating ointment is prepared from, by weight, 40 parts of raw rhubarb, 40 parts of wine-processed scutellaria baicalensis, 30 parts of wine-processed coptis chinensis, 40 parts of radix ranunculi ternati and 30 parts of perfoliote knotweed herb. , 20 parts of vinegar frankincense, 20 parts of raw radix astragali, and 9 parts of borneol. The traditional Chinese medicine composition has the beneficial effects of effectively and quickly relieving pain symptoms of SAT patients, relieving inflammatory response, relieving goiter enlargement degree and recovering thyroid functions, and the curative effect of the traditional Chinese medicine composition is superior to that of pure non-steroidal anti-inflammatory medicine treatment. The external preparation is exact in curative effect, few in adverse reaction, capable of achieving the effect of treating both symptoms and root causes, convenient to use and beneficial to development and application.

The application discloses a processed American ginseng product for treating hypothyroidism, which is prepared from American ginseng as raw material and is obtained through nine times of steaming and drying; the black American ginseng is crushed into coarse powder, and is extracted three times through heating reflux extraction with 50-70% ethanol solution, and each time is 1-3 hours, and the extract is concentrated to obtain the product. The application further discloses application of the processed American ginseng product in preparation of a medicine for treating hypothyroidism. The processed American ginseng product can improve the unbalanced hypothalamus-pituitary-thyroid axis function of a hypothyroidism patient, promote secretion of thyroid hormone, improve thyroid function, and has a remarkable improvement effect on hypothyroidism.